AzTrials
AzTrials

AtherosclerosisPhase 3CANTOSNCT01327846

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

A Phase 3 study testing Canakinumab in people with Atherosclerosis, run by Novartis Pharmaceuticals at 1,131 sites in 40 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Main Study (CACZ885M2301): The purpose of the pivotal phase of this trial was to test the hypothesis that canakinumab treatment of patients with myocardial infarction (MI) at least one month prior to study entry and elevated hsCRP could prevent recurrent cardiovascular events. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Atherosclerosis
What is being tested?
Canakinumab
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
10,066 participants
Where
1,131 sitesin 40 countries
Study dates
11 Apr 2011to 14 Apr 2019
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Main Study Inclusion Criteria:

  • Written informed consent
  • Male, or Female of non-child-bearing potential
  • Age ≥ 18 years.
  • Spontaneous MI at least 30 days before randomization. hsCRP ≥ 2 mg/L

Substudy 1 Inclusion:

  • All Inclusion from Main Study
  • Acquisition of evaluable baseline MRI images of bilateral carotid arteries by the imaging core laboratory

Substudy 2 Inclusion:

  • All inclusion from Main Study
  • T2D at baseline per Main protocol criteria and be on a stable anti-hyperglycemic medication for at least 4 weeks prior to the baseline OGTT test
  • Willing to have the OGTT assessment started before 10 am

Main Study Exclusion Criteria:

  • Pregnant or nursing (lactating) women
  • Women of child-bearing potential
  • Any of the following concomitant diseases
  • Planned coronary revascularization (PCI or CABG)
  • Major non-cardiac surgical or endoscopic procedure within past 6 months
  • Multi-vessel CABG surgery within the past 3 years
  • Symptomatic patients with Class IV heart failure (HF) (New York Heart Association [NYHA].
  • Uncontrolled hypertension
  • Uncontrolled diabetes
  • History or evidence of active tuberculosis (TB) infection Substudy 1 Exclusion
  • All Main exclusion
  • Patients with prior history of carotid angioplasty, stenting, or carotid atherectomy
  • Patients with contraindications to MRI examination (brain aneurysm clip, implanted neural stimulator, implanted cardiac pacemaker, pacemaker wires or defibrillator, prosthetic heart valves, cochlear implant, ocular foreign body or other implanted body, tattoos, implanted insulin pump, metal shrapnel or bullet)
  • Patients prone to claustrophobia or known anxiety disorders
  • BMI > 40 kg/m2 Substudy 2 Exclusion
  • This sub-study does not have any additional exclusion criteria.

Trial locations and contacts

1,131 sites in 40 countries.

1116 sites in 40 countries

United States300 sites

  • Novartis Investigative Site

    Abington, Pennsylvania, 19001

  • Novartis Investigative Site

    Akron, Ohio, 44309

  • Novartis Investigative Site

    Albuquerque, New Mexico, 87102

  • Novartis Investigative Site

    Allen, Texas, 75002-3688

  • Novartis Investigative Site

    Altoona, Pennsylvania, 16602

  • Novartis Investigative Site

    Ames, Iowa, 50010

  • Novartis Investigative Site

    Anchorage, Alaska, 99508

  • Novartis Investigative Site

    Anderson, South Carolina, 29621

  • Novartis Investigative Site

    Ann Arbor, Michigan, 48106

  • Novartis Investigative Site

    Asheboro, North Carolina, 27204

  • Novartis Investigative Site

    Athens, Alabama, 35611

  • Novartis Investigative Site

    Athens, Georgia, 30606

  • Novartis Investigative Site

    Augusta, Georgia, 30904

  • Novartis Investigative Site

    Aurora, Colorado, 80012

  • Novartis Investigative Site

    Baltimore, Maryland, 21204

  • Novartis Investigative Site

    Bartlesville, Oklahoma, 74006

  • Novartis Investigative Site

    Baton Rouge, Louisiana, 70808

  • Novartis Investigative Site

    Baton Rouge, Louisiana, 70816

  • Novartis Investigative Site

    Beaumont, Texas, 77701

  • Novartis Investigative Site

    Beaumont, Texas, 77702

  • Novartis Investigative Site

    Beaver, Pennsylvania, 15009

  • Novartis Investigative Site

    Bedford, Texas, 76021

  • Novartis Investigative Site

    Beltsville, Maryland, 20705

  • Novartis Investigative Site

    Bend, Oregon, 97701

  • Novartis Investigative Site

    Beverly Hills, California, 90211

  • Novartis Investigative Site

    Binghamton, New York, 13901

  • Novartis Investigative Site

    Birmingham, Alabama, 35235-3424

  • Novartis Investigative Site

    Birmingham, Alabama, 35243

  • Novartis Investigative Site

    Birmingham, Alabama, 35294-2041

  • Novartis Investigative Site

    Bloomington, Minnesota, 55420

  • Novartis Investigative Site

    Bountiful, Utah, 84010

  • Novartis Investigative Site

    Bridgeville, Pennsylvania, 15017

  • Novartis Investigative Site

    Brownsville, Texas, 78520

  • Novartis Investigative Site

    Burke, Virginia, 22015

  • Novartis Investigative Site

    Burlington, Massachusetts, 01803

  • Novartis Investigative Site

    Camden, New Jersey, 08103

  • Novartis Investigative Site

    Camp Hill, Pennsylvania, 17011

  • Novartis Investigative Site

    Carmichael, California, 95608

  • Novartis Investigative Site

    Chandler, Arizona, 85224

  • Novartis Investigative Site

    Charlotte, North Carolina, 28277

  • Novartis Investigative Site

    Chelsea, Michigan, 48118

  • Novartis Investigative Site

    Chicago, Illinois, 60611

  • Novartis Investigative Site

    Cincinnati, Ohio, 45219

  • Novartis Investigative Site

    Cincinnati, Ohio, 45245

  • Novartis Investigative Site

    Clearwater, Florida, 33756

  • Novartis Investigative Site

    Cleveland, Ohio, 44109-1998

  • Novartis Investigative Site

    Coeur d'Alene, Idaho, 83814

  • Novartis Investigative Site

    Colorado Springs, Colorado, 80907

  • Novartis Investigative Site

    Columbia, Maryland, 21044

  • Novartis Investigative Site

    Columbia, Missouri, 65212

  • Novartis Investigative Site

    Columbia, South Carolina, 29201

  • Novartis Investigative Site

    Columbus, Ohio, 43235

  • Novartis Investigative Site

    Coral Springs, Florida, 33065

  • Novartis Investigative Site

    Covington, Georgia, 30014

  • Novartis Investigative Site

    Covington, Louisiana, 70433

  • Novartis Investigative Site

    Cumberland, Rhode Island, 02864-1410

  • Novartis Investigative Site

    Cumming, Georgia, 30041

  • Novartis Investigative Site

    Dallas, Texas, 75204

  • Novartis Investigative Site

    Dallas, Texas, 75226

  • Novartis Investigative Site

    Dallas, Texas, 75231

  • Novartis Investigative Site

    Danville, Virginia, 24541

  • Novartis Investigative Site

    Davie, Florida, 33324

  • Novartis Investigative Site

    Dayton, Ohio, 45402

  • Novartis Investigative Site

    Daytona Beach, Florida, 32114

  • Novartis Investigative Site

    Decatur, Georgia, 30033

  • Novartis Investigative Site

    Decatur, Georgia, 30035

  • Novartis Investigative Site

    DeFuniak Springs, Florida, 32435

  • Novartis Investigative Site

    Denver, Colorado, 80204-4507

  • Novartis Investigative Site

    Denver, Colorado, 80206

  • Novartis Investigative Site

    Denver, Colorado, 80218

  • Novartis Investigative Site

    Denver, Colorado, 80220

  • Novartis Investigative Site

    Detroit, Michigan, 48202

  • Novartis Investigative Site

    Doral, Florida, 33136

  • Novartis Investigative Site

    Duluth, Georgia, 30096

  • Novartis Investigative Site

    Duluth, Minnesota, 55805

  • Novartis Investigative Site

    Edina, Minnesota, 55435

  • Novartis Investigative Site

    Endwell, New York, 13760

  • Novartis Investigative Site

    Erie, Pennsylvania, 16507

  • Novartis Investigative Site

    Escondido, California, 92025

  • Novartis Investigative Site

    Evansville, Indiana, 47712

  • Novartis Investigative Site

    Evansville, Indiana, 47714

  • Novartis Investigative Site

    Fairhope, Alabama, 36532

  • Novartis Investigative Site

    Fall River, Massachusetts, 02720

  • Novartis Investigative Site

    Fargo, North Dakota, 58122

  • Novartis Investigative Site

    Fort Mill, South Carolina, 29707

  • Novartis Investigative Site

    Freehold, New Jersey, 07728

  • Novartis Investigative Site

    Fridley, Minnesota, 55432

  • Novartis Investigative Site

    Fullerton, California, 92835

  • Novartis Investigative Site

    Germantown, Tennessee, 38138

  • Novartis Investigative Site

    Glendale, Arizona, 85306

  • Novartis Investigative Site

    Gonzales, Texas, 78629

  • Novartis Investigative Site

    Grand Blanc, Michigan, 48439

  • Novartis Investigative Site

    Grand Forks, North Dakota, 58201

  • Novartis Investigative Site

    Grand Island, Nebraska, 68803

  • Novartis Investigative Site

    Greensboro, North Carolina, 27401

  • Novartis Investigative Site

    Greensboro, North Carolina, 27410

  • Novartis Investigative Site

    Greenville, North Carolina, 27834

  • Novartis Investigative Site

    Greenville, South Carolina, 29605

  • Novartis Investigative Site

    Greenville, Tennessee, 37745

  • Novartis Investigative Site

    Greenville, Texas, 75401

  • Novartis Investigative Site

    Greer, South Carolina, 29651

  • Novartis Investigative Site

    Hattiesburg, Mississippi, 39401

  • Novartis Investigative Site

    Haverhill, Massachusetts, 01830

  • Novartis Investigative Site

    Hershey, Pennsylvania, 17033

  • Novartis Investigative Site

    Hialeah, Florida, 33012

  • Novartis Investigative Site

    Hickory, North Carolina, 28601

  • Novartis Investigative Site

    Hollywood, Florida, 33021

  • Novartis Investigative Site

    Hollywood, Florida, 33312

  • Novartis Investigative Site

    Honolulu, Hawaii, 96814

  • Novartis Investigative Site

    Hopewell, Virginia, 23860

  • Novartis Investigative Site

    Hot Springs, Arkansas, 71913

  • Novartis Investigative Site

    Houma, Louisiana, 70360

  • Novartis Investigative Site

    Houston, Texas, 77025

  • Novartis Investigative Site

    Houston, Texas, 77030

  • Novartis Investigative Site

    Houston, Texas, 77055

  • Novartis Investigative Site

    Houston, Texas, 77064

  • Novartis Investigative Site

    Houston, Texas, 77070

  • Novartis Investigative Site

    Houston, Texas, 77081

  • Novartis Investigative Site

    Huntington Beach, California, 92647

  • Novartis Investigative Site

    Huntsville, Alabama, 35801

  • Novartis Investigative Site

    Irving, Texas, 75039

  • Novartis Investigative Site

    Jackson, Mississippi, 39209

  • Novartis Investigative Site

    Jackson, Tennessee, 38305

  • Novartis Investigative Site

    Jacksonville, Florida, 32204

  • Novartis Investigative Site

    Jacksonville, Florida, 32209-6511

  • Novartis Investigative Site

    Jacksonville, Florida, 32216

  • Novartis Investigative Site

    Jacksonville, Florida, 32223

  • Novartis Investigative Site

    Jacksonville Beach, Florida, 32050

  • Novartis Investigative Site

    Jerseyville, Illinois, 62052

  • Novartis Investigative Site

    Johnson City, Tennessee, 37604

  • Novartis Investigative Site

    Jonesboro, Arkansas, 72401

  • Novartis Investigative Site

    Jupiter, Florida, 33458

  • Novartis Investigative Site

    Kalamazoo, Michigan, 49008

  • Novartis Investigative Site

    Kansas City, Kansas, 66160

  • Novartis Investigative Site

    Kansas City, Missouri, 64111

  • Novartis Investigative Site

    Kew Gardens, New York, 11415

  • Novartis Investigative Site

    Knoxville, Tennessee, 37917

  • Novartis Investigative Site

    Knoxville, Tennessee, 37920

  • Novartis Investigative Site

    Knoxville, Tennessee, 37934

  • Novartis Investigative Site

    Lafayette, Louisiana, 70501

  • Novartis Investigative Site

    Lafayette, Louisiana, 70508

  • Novartis Investigative Site

    Lake Jackson, Texas, 77566

  • Novartis Investigative Site

    Lancaster, California, 93534

  • Novartis Investigative Site

    Las Vegas, Nevada, 89118

  • Novartis Investigative Site

    Layton, Utah, 84041

  • Novartis Investigative Site

    Leander, Texas, 78641

  • Novartis Investigative Site

    Lexington, Kentucky, 40509

  • Novartis Investigative Site

    Lincoln, Nebraska, 68516

  • Novartis Investigative Site

    Little Rock, Arkansas, 72204

  • Novartis Investigative Site

    Livingston, Texas, 77351

  • Novartis Investigative Site

    Lodi, New Jersey, 07644

  • Novartis Investigative Site

    Loma Linda, California, 92354

  • Novartis Investigative Site

    Loma Linda, California, 92357

  • Novartis Investigative Site

    Lombard, Illinois, 60148

  • Novartis Investigative Site

    Long Beach, California, 90806

  • Novartis Investigative Site

    Los Angeles, California, 90033

  • Novartis Investigative Site

    Los Angeles, California, 90073

  • Novartis Investigative Site

    Los Gatos, California, 95032

  • Novartis Investigative Site

    Louisville, Kentucky, 40206

  • Novartis Investigative Site

    Lufkin, Texas, 75904

  • Novartis Investigative Site

    Macon, Georgia, 31201

  • Novartis Investigative Site

    Madison, Wisconsin, 53713

  • Novartis Investigative Site

    Madisonville, Kentucky, 42431

  • Novartis Investigative Site

    Mandeville, Louisiana, 70471

  • Novartis Investigative Site

    Marion, Ohio, 43302

  • Novartis Investigative Site

    Marshall, Texas, 75670

  • Novartis Investigative Site

    McAllen, Texas, 78501

  • Novartis Investigative Site

    McKinney, Texas, 75069

  • Novartis Investigative Site

    Melrose Park, Illinois, 60160

  • Novartis Investigative Site

    Memphis, Tennessee, 38120

  • Novartis Investigative Site

    Metairie, Louisiana, 70001

  • Novartis Investigative Site

    Metairie, Louisiana, 70006

  • Novartis Investigative Site

    Miami, Florida, 33126

  • Novartis Investigative Site

    Miami, Florida, 33135

  • Novartis Investigative Site

    Miami, Florida, 33155

  • Novartis Investigative Site

    Miami, Florida, 33176

  • Novartis Investigative Site

    Miami Beach, Florida, 33140

  • Novartis Investigative Site

    Midland, Michigan, 48640

  • Novartis Investigative Site

    Minden, Louisiana, 71055

  • Novartis Investigative Site

    Mineola, New York, 11501

  • Novartis Investigative Site

    Minneapolis, Minnesota, 55433

  • Novartis Investigative Site

    Mission Viejo, California, 92691

  • Novartis Investigative Site

    Mobile, Alabama, 36604

  • Novartis Investigative Site

    Mobile, Alabama, 36608

  • Novartis Investigative Site

    Mobile, Alabama, 36617-2293

  • Novartis Investigative Site

    Moncks Corner, South Carolina, 29461

  • Novartis Investigative Site

    Mooresville, North Carolina, 28117

  • Novartis Investigative Site

    Mt. Pleasant, South Carolina, 29464

  • Novartis Investigative Site

    Naples, Florida, 34119

  • Novartis Investigative Site

    Nashua, New Hampshire, 03060

  • Novartis Investigative Site

    New Brunswick, New Jersey, 08901

  • Novartis Investigative Site

    New Orleans, Louisiana, 70115

  • Novartis Investigative Site

    New Orleans, Louisiana, 70119

  • Novartis Investigative Site

    New York, New York, 10003

  • Novartis Investigative Site

    New York, New York, 10016

  • Novartis Investigative Site

    New York, New York, 10035

  • Novartis Investigative Site

    Newark, Delaware, 19713

  • Novartis Investigative Site

    Newport Beach, California, 92663

  • Novartis Investigative Site

    North Myrtle Beach, South Carolina, 29582

  • Novartis Investigative Site

    Northridge, California, 91325

  • Novartis Investigative Site

    Norwich, Connecticut, 06360

  • Novartis Investigative Site

    Novi, Michigan, 48374

  • Novartis Investigative Site

    Ocean City, New Jersey, 07712

  • Novartis Investigative Site

    Oceanside, California, 92056

  • Novartis Investigative Site

    Odessa, Texas, 79761

  • Novartis Investigative Site

    Oklahoma City, Oklahoma, 73120

  • Novartis Investigative Site

    Omaha, Nebraska, 68114

  • Novartis Investigative Site

    Omaha, Nebraska, 68131

  • Novartis Investigative Site

    Omaha, Nebraska, 68134

  • Novartis Investigative Site

    Opelousas, Louisiana, 70570

  • Novartis Investigative Site

    Orangeburg, South Carolina, 29115

  • Novartis Investigative Site

    Orangevale, California, 95662

  • Novartis Investigative Site

    Orlando, Florida, 32822

  • Novartis Investigative Site

    Overland Park, Kansas, 66204

  • Novartis Investigative Site

    Owensboro, Kentucky, 42303

  • Novartis Investigative Site

    Palm Springs, California, 92262

  • Novartis Investigative Site

    Pasadena, California, 91105

  • Novartis Investigative Site

    Pembroke Pines, Florida, 33024

  • Novartis Investigative Site

    Peoria, Illinois, 61602

  • Novartis Investigative Site

    Petoskey, Michigan, 49770

  • Novartis Investigative Site

    Phoenix, Arizona, 85018

  • Novartis Investigative Site

    Phoenix, Arizona, 85032

  • Novartis Investigative Site

    Picayune, Mississippi, 39466

  • Novartis Investigative Site

    Pinehurst, North Carolina, 28374

  • Novartis Investigative Site

    Pinellas Park, Florida, 33781

  • Novartis Investigative Site

    Pittsburgh, Pennsylvania, 15216

  • Novartis Investigative Site

    Pittsburgh, Pennsylvania, 15236

  • Novartis Investigative Site

    Pittsburgh, Pennsylvania, 15243

  • Novartis Investigative Site

    Pomona, California, 91767

  • Novartis Investigative Site

    Pomona, New Jersey, 08240

  • Novartis Investigative Site

    Port Charlotte, Florida, 33952

  • Novartis Investigative Site

    Port Orange, Florida, 32127

  • Novartis Investigative Site

    Port Orchard, Washington, 98366

  • Novartis Investigative Site

    Portland, Maine, 04102

  • Novartis Investigative Site

    Portland, Oregon, 97225

  • Novartis Investigative Site

    Pottstown, Pennsylvania, 19464

  • Novartis Investigative Site

    Providence, Rhode Island, 02904

  • Novartis Investigative Site

    Providence, Rhode Island, 02906

  • Novartis Investigative Site

    Rapid City, South Dakota, 57701

  • Novartis Investigative Site

    Renton, Washington, 98057

  • Novartis Investigative Site

    Richmond, Virginia, 23249

  • Novartis Investigative Site

    Richmond, Virginia, 23298

  • Novartis Investigative Site

    Ridgewood, New Jersey, 07450

  • Novartis Investigative Site

    Robbinsdale, Minnesota, 55422

  • Novartis Investigative Site

    Rochester, New York, 14609

  • Novartis Investigative Site

    Rochester, New York, 14621

  • Novartis Investigative Site

    Roswell, Georgia, 30076

  • Novartis Investigative Site

    Royal Oak, Michigan, 48073

  • Novartis Investigative Site

    Sacramento, California, 95816

  • Novartis Investigative Site

    Sacramento, California, 95819

  • Novartis Investigative Site

    Saginaw, Michigan, 48601

  • Novartis Investigative Site

    Saint Cloud, Minnesota, 56303

  • Novartis Investigative Site

    Saint Paul, Minnesota, 55102

  • Novartis Investigative Site

    Salisbury, North Carolina, 28144

  • Novartis Investigative Site

    Salt Lake City, Utah, 84102

  • Novartis Investigative Site

    Salt Lake City, Utah, 84107

  • Novartis Investigative Site

    Salt Lake City, Utah, 84124

  • Novartis Investigative Site

    San Antonio, Texas, 78212

  • Novartis Investigative Site

    San Antonio, Texas, 78229-3900

  • Novartis Investigative Site

    San Antonio, Texas, 78229-4801

  • Novartis Investigative Site

    San Antonio, Texas, 78229

  • Novartis Investigative Site

    San Antonio, Texas, 78234

  • Novartis Investigative Site

    San Antonio, Texas, 78238-7676

  • Novartis Investigative Site

    San Antonio, Texas, 78258

  • Novartis Investigative Site

    San Diego, California, 92101

  • Novartis Investigative Site

    San Diego, California, 92120

  • Novartis Investigative Site

    San Diego, California, 92128

  • Novartis Investigative Site

    San Diego, California, 92161

  • Novartis Investigative Site

    San Francisco, California, 94143-0792

  • Novartis Investigative Site

    Sanford, North Carolina, 27330

  • Novartis Investigative Site

    Santa Ana, California, 92704

  • Novartis Investigative Site

    Santa Rosa, California, 95405

  • Novartis Investigative Site

    Sarasota, Florida, 34239

  • Novartis Investigative Site

    Savannah, Georgia, 31406

  • Novartis Investigative Site

    Seattle, Washington, 98104

  • Novartis Investigative Site

    Seattle, Washington, 98122

  • Novartis Investigative Site

    Shreveport, Louisiana, 71101

  • Novartis Investigative Site

    Shreveport, Louisiana, 71103

  • Novartis Investigative Site

    Sioux Falls, South Dakota, 57104

  • Novartis Investigative Site

    Slidell, Louisiana, 70458

  • Novartis Investigative Site

    South Miami, Florida, 33143

  • Novartis Investigative Site

    Springfield, Missouri, 65807

  • Novartis Investigative Site

    St Louis, Missouri, 63110

  • Novartis Investigative Site

    St Louis, Missouri, 63128

  • Novartis Investigative Site

    St Louis, Missouri, 63141

  • Novartis Investigative Site

    Statesville, North Carolina, 28625

  • Novartis Investigative Site

    Sugar Land, Texas, 77479

  • Novartis Investigative Site

    Tacoma, Washington, 98405

  • Novartis Investigative Site

    Tampa, Florida, 33613

  • Novartis Investigative Site

    Tampa, Florida, 33624

  • Novartis Investigative Site

    Temple, Texas, 76508

  • Novartis Investigative Site

    Thomasville, Georgia, 31792

  • Novartis Investigative Site

    Tomball, Texas, 77375

  • Novartis Investigative Site

    Topeka, Kansas, 66606

  • Novartis Investigative Site

    Torrance, California, 90502

  • Novartis Investigative Site

    Tulsa, Oklahoma, 74133

  • Novartis Investigative Site

    Tustin, California, 92780

  • Novartis Investigative Site

    Uniontown, Pennsylvania, 15401

  • Novartis Investigative Site

    Varnville, South Carolina, 29944

  • Novartis Investigative Site

    Visalia, California, 93291

Other trials in United States

Germany83 sites

  • Novartis Investigative Site

    Bad Krozingen, 79189

  • Novartis Investigative Site

    Balve, 58802

  • Novartis Investigative Site

    Berlin, 10117

  • Novartis Investigative Site

    Berlin, 10367

  • Novartis Investigative Site

    Berlin, 10629

  • Novartis Investigative Site

    Berlin, 10789

  • Novartis Investigative Site

    Berlin, 12627

  • Novartis Investigative Site

    Berlin, 13055

  • Novartis Investigative Site

    Berlin, 13353

  • Novartis Investigative Site

    Bochum, 44787

  • Novartis Investigative Site

    Borna, 04552

  • Novartis Investigative Site

    Chemnitz, 09122

  • Novartis Investigative Site

    Chemnitz, 09130

  • Novartis Investigative Site

    Cologne, 51065

  • Novartis Investigative Site

    Dillingen, 66763

  • Novartis Investigative Site

    Dinslaken, 46535

  • Novartis Investigative Site

    Dortmund, 44137

  • Novartis Investigative Site

    Dresden, 01067

  • Novartis Investigative Site

    Dresden, 01069

  • Novartis Investigative Site

    Dresden, 01277

  • Novartis Investigative Site

    Dresden, 01307

  • Novartis Investigative Site

    Dresden, 01309

  • Novartis Investigative Site

    Duisburg, 47137

  • Novartis Investigative Site

    Düsseldorf, 40597

  • Novartis Investigative Site

    Ebersbach, 02730

  • Novartis Investigative Site

    Elsterwerda, 04910

  • Novartis Investigative Site

    Erlangen, 91054

  • Novartis Investigative Site

    Essen, 45136

  • Novartis Investigative Site

    Essen, 45276

  • Novartis Investigative Site

    Essen, 45355

  • Novartis Investigative Site

    Falkensee, 14612

  • Novartis Investigative Site

    Frankfurt, 60488

  • Novartis Investigative Site

    Frankfurt, 60594

  • Novartis Investigative Site

    Frankfurt am Main, 60313

  • Novartis Investigative Site

    Freiburg im Breisgau, 79106

  • Novartis Investigative Site

    Fulda, 36037

  • Novartis Investigative Site

    Giengen an der Brenz, 89537

  • Novartis Investigative Site

    Görlitz, 02826

  • Novartis Investigative Site

    Haag, 83527

  • Novartis Investigative Site

    Halle, 06120

  • Novartis Investigative Site

    Hamburg, 20246

  • Novartis Investigative Site

    Hamburg, 22041

  • Novartis Investigative Site

    Hamburg, 22177

  • Novartis Investigative Site

    Hamburg, 22393

  • Novartis Investigative Site

    Hamburg, 22765

  • Novartis Investigative Site

    Heidelberg, 69120

  • Novartis Investigative Site

    Heilbronn, 74078

  • Novartis Investigative Site

    Huy / OT Anderbeck, 38836

  • Novartis Investigative Site

    Jerichow, 39319

  • Novartis Investigative Site

    Kallstadt, 67169

  • Novartis Investigative Site

    Kamp-Lintfort, 47475

  • Novartis Investigative Site

    Kassel, 34127

  • Novartis Investigative Site

    Kiel, 24119

  • Novartis Investigative Site

    Koblenz, 56068

  • Novartis Investigative Site

    Künzing, 94550

  • Novartis Investigative Site

    Leipzig, 04103

  • Novartis Investigative Site

    Leipzig, 04107

  • Novartis Investigative Site

    Ludwigshafen, 67063

  • Novartis Investigative Site

    Lüneburg, 21339

  • Novartis Investigative Site

    Magdeburg, 39112

  • Novartis Investigative Site

    Mainz, 55116

  • Novartis Investigative Site

    Mainz, 55131

  • Novartis Investigative Site

    Mayen, 56727

  • Novartis Investigative Site

    Meissen, 01662

  • Novartis Investigative Site

    Meißen, 01662

  • Novartis Investigative Site

    Muehldorf Am Inn, 84453

  • Novartis Investigative Site

    Muehlheim An Der Ruhr, North Rhine-Westphalia, 45468

  • Novartis Investigative Site

    Mühlhausen, 99974

  • Novartis Investigative Site

    Neuhofen, 67141

  • Novartis Investigative Site

    Neunkirchen, 66539

  • Novartis Investigative Site

    Northeim, 37154

  • Novartis Investigative Site

    Nuremberg, 90402

  • Novartis Investigative Site

    Oelde, 59302

  • Novartis Investigative Site

    Oschatz, 04758

  • Novartis Investigative Site

    Paderborn, 33098

  • Novartis Investigative Site

    Potsdam, 14469

  • Novartis Investigative Site

    Rednitzhembach, 91126

  • Novartis Investigative Site

    Reinfeld, 23858

  • Novartis Investigative Site

    Rostock, 06120

  • Novartis Investigative Site

    Rüdersdorf, 15562

  • Novartis Investigative Site

    Siegen, 57072

  • Novartis Investigative Site

    Ulm, 89081

  • Novartis Investigative Site

    Wolmirstedt, 39326

Other trials in Germany

Argentina53 sites

  • Novartis Investigative Site

    Bahía Blanca, Buenos Aires, B8000AAT

  • Novartis Investigative Site

    CABA, Buenos Aires, 1428

  • Novartis Investigative Site

    CABA, Buenos Aires, C1056ABJ

  • Novartis Investigative Site

    CABA, Buenos Aires, C1221ADC

  • Novartis Investigative Site

    CABA, Buenos Aires, C1425AGC

  • Novartis Investigative Site

    CABA, Buenos Aires, C1425BWO

  • Novartis Investigative Site

    CABA, Buenos Aires, C1440AAD

  • Novartis Investigative Site

    CABA, Buenos Aires F.D., C1179AAB

  • Novartis Investigative Site

    CABA, Buenos Aires F.D., C1430CKE

  • Novartis Investigative Site

    CABA, C1119ACN

  • Novartis Investigative Site

    Cipolletti, Río Negro Province, 8324

  • Novartis Investigative Site

    Córdoba, 5000

  • Novartis Investigative Site

    Córdoba, X5000AAJ

  • Novartis Investigative Site

    Córdoba, X5000AAW

  • Novartis Investigative Site

    Córdoba, X5000AAX

  • Novartis Investigative Site

    Córdoba, X5000EPU

  • Novartis Investigative Site

    Córdoba, X5000JJS

  • Novartis Investigative Site

    Córdoba, X5003DCE

  • Novartis Investigative Site

    Córdoba, X5003DCP

  • Novartis Investigative Site

    Córdoba, X5006CBI

  • Novartis Investigative Site

    Córdoba, X5009BSN

  • Novartis Investigative Site

    Córdoba, X5022CPU

  • Novartis Investigative Site

    Córdoba, X5220XAO

  • Novartis Investigative Site

    Corrientes, W3400CBI

  • Novartis Investigative Site

    Corrientes, W3400CLH

  • Novartis Investigative Site

    Corrientes, W3400

  • Novartis Investigative Site

    Corrientes, W3410AVV

  • Novartis Investigative Site

    Formosa, P3600

  • Novartis Investigative Site

    Formosa, P3634XAR

  • Novartis Investigative Site

    Mar del Plata, Buenos Aires, 7600

  • Novartis Investigative Site

    Mar del Plata, Buenos Aires, B7600

  • Novartis Investigative Site

    Posadas, Misiones Province, N3300AHX

  • Novartis Investigative Site

    Quilmes, Buenos Aires, B1878DVB

  • Novartis Investigative Site

    Quilmes, Buenos Aires, B1878GEG

  • Novartis Investigative Site

    Ramos Mejía, Buenos Aires, B1704ETD

  • Novartis Investigative Site

    Rosario, Santa Fe Province, S2000CXP

  • Novartis Investigative Site

    Rosario, Santa Fe Province, S2000DSV

  • Novartis Investigative Site

    Rosario, Santa Fe Province, S2000

  • Novartis Investigative Site

    Salta, 4400

  • Novartis Investigative Site

    San Isidro, Buenos Aires, B1642DCD

  • Novartis Investigative Site

    San Luis, D5702JRS

  • Novartis Investigative Site

    San Miguel de Tucumán, San Miguel de Tucuman, T4000ICL

  • Novartis Investigative Site

    San Miguel de Tucumán, Tucumán Province, T4000EBR

  • Novartis Investigative Site

    San Miguel de Tucumán, Tucumán Province, T4000IFL

  • Novartis Investigative Site

    San Miguel de Tucumán, Tucumán Province, T4000IIH

  • Novartis Investigative Site

    San Miguel de Tucumán, T4000HXU

  • Novartis Investigative Site

    San Nicolás de los Arroyos, Buenos Aires, B2900DMH

  • Novartis Investigative Site

    San Salvador de Jujuy, Jujuy Province, Y4600ABF

  • Novartis Investigative Site

    Santa Fe, S3000EOZ

  • Novartis Investigative Site

    Santa Fe, S3000EPV

  • Novartis Investigative Site

    Santa Fe, S3000FWO

  • Novartis Investigative Site

    Santiago del Estero, G4200AQK

  • Novartis Investigative Site

    Zárate, Buenos Aires, 2800

Other trials in Argentina

Russia48 sites

  • Novartis Investigative Site

    Chelyabinsk, 454000

  • Novartis Investigative Site

    Chelyabinsk, 454047

  • Novartis Investigative Site

    Chelyabinsk, 454048

  • Novartis Investigative Site

    Izhevsk, 426063

  • Novartis Investigative Site

    Kazan', 420012

  • Novartis Investigative Site

    Kemerovo, 650029

  • Novartis Investigative Site

    Kirov, 610027

  • Novartis Investigative Site

    Kirov, 610035

  • Novartis Investigative Site

    Krasnodar, 350086

  • Novartis Investigative Site

    Moscow, 111539

  • Novartis Investigative Site

    Moscow, 117198

  • Novartis Investigative Site

    Moscow, 117556

  • Novartis Investigative Site

    Moscow, 119881

  • Novartis Investigative Site

    Moscow, 125284

  • Novartis Investigative Site

    Moscow, 127018

  • Novartis Investigative Site

    Moscow, 127473

  • Novartis Investigative Site

    Novosibirsk, 630087

  • Novartis Investigative Site

    Penza, 440067

  • Novartis Investigative Site

    Perm, 614097

  • Novartis Investigative Site

    Perm, 614107

  • Novartis Investigative Site

    Petrozavodsk, 185019

  • Novartis Investigative Site

    Ryazan, 390026

  • Novartis Investigative Site

    Saint Petersburg, 190013

  • Novartis Investigative Site

    Saint Petersburg, 192257

  • Novartis Investigative Site

    Saint Petersburg, 193163

  • Novartis Investigative Site

    Saint Petersburg, 194044

  • Novartis Investigative Site

    Saint Petersburg, 194295

  • Novartis Investigative Site

    Saint Petersburg, 195067

  • Novartis Investigative Site

    Saint Petersburg, 196084

  • Novartis Investigative Site

    Saint Petersburg, 197022

  • Novartis Investigative Site

    Saint Petersburg, 197110

  • Novartis Investigative Site

    Saint Petersburg, 197341

  • Novartis Investigative Site

    Saint Petersburg, 199106

  • Novartis Investigative Site

    Samara, 443070

  • Novartis Investigative Site

    Samara, 443096

  • Novartis Investigative Site

    Saratov, 410012

  • Novartis Investigative Site

    Saratov, 410028

  • Novartis Investigative Site

    Sestroretsk, 197706

  • Novartis Investigative Site

    Smolensk, 214018

  • Novartis Investigative Site

    Syktyvkar, 167981

  • Novartis Investigative Site

    Tomsk, 634012

  • Novartis Investigative Site

    Tyumen, 625026

  • Novartis Investigative Site

    Vladimir, 600020

  • Novartis Investigative Site

    Yaroslavl, 150047

  • Novartis Investigative Site

    Yekaterinburg, 620028

  • Novartis Investigative Site

    Yekaterinburg, 620102

  • Novartis Investigative Site

    Yekaterinburg, 620109

  • Novartis Investigative Site

    Yekaterinburg, 620137

Other trials in Russia

India46 sites

  • Novartis Investigative Site

    Ahmedabad, Gujarat, 380 051

  • Novartis Investigative Site

    Ahmedabad, Gujarat, 380006

  • Novartis Investigative Site

    Ahmedabad, Gujarat, 380054

  • Novartis Investigative Site

    Ahmedabad, Gujarat, 382428

  • Novartis Investigative Site

    Ahmedabad, 380025

  • Novartis Investigative Site

    Bangalore, Karnataka, 560 055

  • Novartis Investigative Site

    Bengaluru, Karnataka, 560034

  • Novartis Investigative Site

    Bikaner, Rajasthan, 334003

  • Novartis Investigative Site

    Chennai, Tamil Nadu, 600081

  • Novartis Investigative Site

    Coimbatore, Tamil Nadu, 641 018

  • Novartis Investigative Site

    Coimbatore, Tamil Nadu, 641037

  • Novartis Investigative Site

    Ghaziabad, Uttar Pradesh

  • Novartis Investigative Site

    Guntur, Andhrapradesh, 522001

  • Novartis Investigative Site

    Hyderabad, Andhra Pradesh, 500001

  • Novartis Investigative Site

    Hyderabad, Andhra Pradesh

  • Novartis Investigative Site

    Hyderabad, Telangana, 500 063

  • Novartis Investigative Site

    Jaipur, Rajasthan, 302016

  • Novartis Investigative Site

    Jaipur, Rajasthan, 302024

  • Novartis Investigative Site

    Kochi, Kerala, 682 018

  • Novartis Investigative Site

    Lucknow, Uttar Pradesh, 226005

  • Novartis Investigative Site

    Ludhiana, Punjab, 141002

  • Novartis Investigative Site

    Ludhiana, Punjab, 141012

  • Novartis Investigative Site

    Ludhiana, Punjab, 141421

  • Novartis Investigative Site

    Madurai, Tamil Nadu, 625107

  • Novartis Investigative Site

    Manipal, Karnataka, 576104

  • Novartis Investigative Site

    Mohali, Punjab, 160 062

  • Novartis Investigative Site

    Nagpur, Maharashtra, 400012

  • Novartis Investigative Site

    Nagpur, Maharashtra, 440 010

  • Novartis Investigative Site

    Nagpur, Maharashtra, 44000033

  • Novartis Investigative Site

    Nagpur, Maharashtra, 440012

  • Novartis Investigative Site

    Nampally, Andhra Pradesh, 500 001

  • Novartis Investigative Site

    Nashik, Maharashtra, 422 005

  • Novartis Investigative Site

    Nellore, Andhra Pradesh, 524 003

  • Novartis Investigative Site

    New Delhi, National Capital Territory of Delhi, 110060

  • Novartis Investigative Site

    Pune, Maharashtra, 411004

  • Novartis Investigative Site

    Pune, Maharashtra, 411005

  • Novartis Investigative Site

    Rajasthan, Rajasthan, 324005

  • Novartis Investigative Site

    Secunderabad, Telangana, 500003

  • Novartis Investigative Site

    Surat, Gujarat, 395 002

  • Novartis Investigative Site

    Surat, Gujarat, 395001

  • Novartis Investigative Site

    Tirupati, Andhra Pradesh, 517 5-7

  • Novartis Investigative Site

    Vadodara, Gujarat, 390015

  • Novartis Investigative Site

    Varanasi, Uttar Pradesh, 224105

  • Novartis Investigative Site

    Vijayawada, Andhra Pradesh, 520 008

  • Novartis Investigative Site

    Vijayawada, Andhra Pradesh, 520010

  • Novartis Investigative Site

    Visakhapatnam, Andhra Pradesh, 530 013

Other trials in India

Japan42 sites

  • Novartis Investigative Site

    Amagasaki, Hyōgo, 660 8550

  • Novartis Investigative Site

    Amagasaki, Hyōgo, 661-0976

  • Novartis Investigative Site

    Bunkyo-ku, Tokyo, 113-8603

  • Novartis Investigative Site

    Chiyoda-ku, Tokyo, 101-8309

  • Novartis Investigative Site

    Chiyoda-ku, Tokyo, 101-8643

  • Novartis Investigative Site

    Fuchū, Tokyo, 183-0003

  • Novartis Investigative Site

    Fujioka, Gunma, 375-8503

  • Novartis Investigative Site

    Funabashi, Chiba, 273-8588

  • Novartis Investigative Site

    Hatsukaichi, Hiroshima, 738 8503

  • Novartis Investigative Site

    Higashiibaraki-gun, Ibaraki, 311-3193

  • Novartis Investigative Site

    Hirakata, Osaka, 573-0153

  • Novartis Investigative Site

    Hitachi, Ibaraki, 317-0077

  • Novartis Investigative Site

    Ichinomiya, Aichi-ken, 491-8551

  • Novartis Investigative Site

    Itabashi-ku, Tokyo, 173-8610

  • Novartis Investigative Site

    Kasuga, Fukuoka, 816-0864

  • Novartis Investigative Site

    Komatsushimachō, Tokushima, 773-8502

  • Novartis Investigative Site

    Kumamoto, Kumamoto, 860-8556

  • Novartis Investigative Site

    Kurume, Fukuoka, 830-8577

  • Novartis Investigative Site

    Kusatsu, Shiga, 525-0014

  • Novartis Investigative Site

    Kyoto, Kyoto, 607-8062

  • Novartis Investigative Site

    Matsudo, Chiba, 270-2251

  • Novartis Investigative Site

    Matsudo, Chiba, 271 0077

  • Novartis Investigative Site

    Nagano, Nagano, 380 0814

  • Novartis Investigative Site

    Nagoya, Aichi-ken, 453-8511

  • Novartis Investigative Site

    Nishinomiya, Hyōgo, 663 8501

  • Novartis Investigative Site

    Ōgaki, Gifu, 503-8502

  • Novartis Investigative Site

    Onga-gun, Fukuoka, 807-0051

  • Novartis Investigative Site

    Osaka, Osaka, 543-0035

  • Novartis Investigative Site

    Osaka, Osaka, 543-8555

  • Novartis Investigative Site

    Osaka, Osaka, 558-8558

  • Novartis Investigative Site

    Sakaidechō, Kagawa-ken, 762-0007

  • Novartis Investigative Site

    Sayama, Saitama, 350-1305

  • Novartis Investigative Site

    Sendai, Miyagi, 980 8574

  • Novartis Investigative Site

    Sendai, Miyagi, 983 8520

  • Novartis Investigative Site

    Seto, Aichi-ken, 489-8642

  • Novartis Investigative Site

    Takamatsu, Kagawa-ken, 760 8557

  • Novartis Investigative Site

    Takarazuka, Hyōgo, 665-0022

  • Novartis Investigative Site

    Takasaki, Gunma, 370-0036

  • Novartis Investigative Site

    Takatsuki, Osaka, 569-0852

  • Novartis Investigative Site

    Tokorozawa, Saitama, 359-1142

  • Novartis Investigative Site

    Yokohama, Kanagawa, 234-0054

  • Novartis Investigative Site

    Yukuhashi, Fukuoka, 824-0026

Other trials in Japan

Canada38 sites

  • Novartis Investigative Site

    Cambridge, Ontario, N1R 6V6

  • Novartis Investigative Site

    Drummondville, Quebec, J2B 7T1

  • Novartis Investigative Site

    Etobicoke, Ontario, M9V 4B4

  • Novartis Investigative Site

    Gatineau, Quebec, J8Y 6S8

  • Novartis Investigative Site

    Granby, Quebec, J2G 1T7

  • Novartis Investigative Site

    Halifax, Nova Scotia, B3H 3A7

  • Novartis Investigative Site

    Hamilton, Ontario, L8L 2X2

  • Novartis Investigative Site

    Joliette, Quebec, J6E 6J2

  • Novartis Investigative Site

    Kitchener, Ontario, N2M 5N4

  • Novartis Investigative Site

    Lachine, Quebec, H8S 2E4

  • Novartis Investigative Site

    Laval, Quebec, H7M 3L9

  • Novartis Investigative Site

    Lévis, Quebec, G6V 4Z5

  • Novartis Investigative Site

    Longueuil, Quebec, J4M 2X1

  • Novartis Investigative Site

    Mississauga, Ontario, L5K 2L3

  • Novartis Investigative Site

    Montreal, Quebec, H3G 1A4

  • Novartis Investigative Site

    Montreal, Quebec, H4J 1C5

  • Novartis Investigative Site

    Mount Pearl, Newfoundland and Labrador, A1N 1W7

  • Novartis Investigative Site

    New Westminster, British Columbia, V3L 3W4

  • Novartis Investigative Site

    Newmarket, Ontario, L3Y 2P7

  • Novartis Investigative Site

    Newmarket, Ontario, L3Y 8C3

  • Novartis Investigative Site

    Ottawa, Ontario, K1Y 4W7

  • Novartis Investigative Site

    Peterborough, Ontario, K9J 0B2

  • Novartis Investigative Site

    Québec, Quebec, G1G 3Y8

  • Novartis Investigative Site

    Québec, Quebec, G1V 4G2

  • Novartis Investigative Site

    Québec, Quebec, G3K 2P8

  • Novartis Investigative Site

    Saint-Jean-sur-Richelieu, Quebec, J3A 1J2

  • Novartis Investigative Site

    Sainte-Foy, Quebec, G1V 4G5

  • Novartis Investigative Site

    Saskatoon, Saskatchewan, S7H 5M3

  • Novartis Investigative Site

    Scarborough Village, Ontario, M1P 2V5

  • Novartis Investigative Site

    Sherbrooke, Quebec, J1G-2E8

  • Novartis Investigative Site

    Ste-Foy, Quebec, G1W 4R4

  • Novartis Investigative Site

    Surrey, British Columbia, V3V 0C6

  • Novartis Investigative Site

    Terrebonne, Quebec, J6V 2H2

  • Novartis Investigative Site

    Thetford-Mines, Quebec, G6G 2V4

  • Novartis Investigative Site

    Toronto, Ontario, M5B 1N9

  • Novartis Investigative Site

    Toronto, Ontario, M9W 4L6

  • Novartis Investigative Site

    Victoria, British Columbia, V8R4R2

  • Novartis Investigative Site

    Winnipeg, Manitoba, R2V 4W3

Other trials in Canada

Italy37 sites

  • Novartis Investigative Site

    Ancona, AN, 60128

  • Novartis Investigative Site

    Bergamo, BG, 24127

  • Novartis Investigative Site

    Brescia, BS, 25123

  • Novartis Investigative Site

    Casorate Primo, PV, 27022

  • Novartis Investigative Site

    Catanzaro, CZ, 88100

  • Novartis Investigative Site

    Chieti, CH, 66100

  • Novartis Investigative Site

    Cona, FE, 44100

  • Novartis Investigative Site

    Cortona, AR, 52044

  • Novartis Investigative Site

    Fermo, AP, 63023

  • Novartis Investigative Site

    Florence, FI, 50134

  • Novartis Investigative Site

    Foggia, FG, 71100

  • Novartis Investigative Site

    Massa, MS, 54100

  • Novartis Investigative Site

    Milan, MI, 20100

  • Novartis Investigative Site

    Milan, MI, 20132

  • Novartis Investigative Site

    Milan, MI, 20145

  • Novartis Investigative Site

    Monserrato, CA, 09042

  • Novartis Investigative Site

    Montichiari, BS, 25018

  • Novartis Investigative Site

    Naples, 80131

  • Novartis Investigative Site

    Novara, 28100

  • Novartis Investigative Site

    Palermo, PA, 90129

  • Novartis Investigative Site

    Palmanova, UD, 33057

  • Novartis Investigative Site

    Parma, PR, 43100

  • Novartis Investigative Site

    Pavia, PV, 27100

  • Novartis Investigative Site

    Piacenza, PC, 29100

  • Novartis Investigative Site

    Pisa, PI, 56126

  • Novartis Investigative Site

    Pozzilli, IS, 86077

  • Novartis Investigative Site

    Roma, RM, 00161

  • Novartis Investigative Site

    Roma, RM, 00168

  • Novartis Investigative Site

    Roma, RM, 00189

  • Novartis Investigative Site

    Rozzano, MI, 20089

  • Novartis Investigative Site

    San Daniele del Friuli, UD, 33038

  • Novartis Investigative Site

    Santa Maria Capua Vetere, CE, 81055

  • Novartis Investigative Site

    Sassari, SS, 07100

  • Novartis Investigative Site

    Soriano Calabro, VV, 89831

  • Novartis Investigative Site

    Treviglio, BG, 24047

  • Novartis Investigative Site

    Verona, VR, 37134

  • Novartis Investigative Site

    Veruno, 28010

Other trials in Italy

Brazil34 sites

  • Novartis Investigative Site

    Belém, Pará, 66087-660

  • Novartis Investigative Site

    Belo Horizonte, Minas Gerais, 30130-060

  • Novartis Investigative Site

    Belo Horizonte, Minas Gerais, 30150-221

  • Novartis Investigative Site

    Blumenau, Santa Catarina, 89020 430

  • Novartis Investigative Site

    Brasília, Federal District, 70390-903

  • Novartis Investigative Site

    Brasília, Federal District, 70658-700

  • Novartis Investigative Site

    Campinas, São Paulo, 13010-001

  • Novartis Investigative Site

    Campinas, São Paulo, 13020-431

  • Novartis Investigative Site

    Campinas, São Paulo, 13060 080

  • Novartis Investigative Site

    Campo Grande, Mato Grosso do Sul, 79080-190

  • Novartis Investigative Site

    Curitiba, Paraná, 80730-150

  • Novartis Investigative Site

    Fortaleza, Ceará, 60430 370

  • Novartis Investigative Site

    Goiânia, Goiás, 74223-130

  • Novartis Investigative Site

    Goiânia, Goiás, 74605-020

  • Novartis Investigative Site

    Passo Fundo, Rio Grande do Sul, 99010-080

  • Novartis Investigative Site

    Pelotas, Rio Grande do Sul, 96015-290

  • Novartis Investigative Site

    Porto Alegre, Rio Grande do Sul, 90560-030

  • Novartis Investigative Site

    Porto Alegre, Rio Grande do Sul, 90610-000

  • Novartis Investigative Site

    Porto Alegre, Rio Grande do Sul, 90620 001

  • Novartis Investigative Site

    Porto Alegre, Rio Grande do Sul, 90880-480

  • Novartis Investigative Site

    Porto Alegre, Rio Grande do Sul, 91350 200

  • Novartis Investigative Site

    Recife, Pernambuco, 52051-380

  • Novartis Investigative Site

    Salvador, Estado de Bahia, 40050-410

  • Novartis Investigative Site

    Salvador, Estado de Bahia, 40140-110

  • Novartis Investigative Site

    Santo André, São Paulo, 09190-615

  • Novartis Investigative Site

    São José do Rio Preto, São Paulo, 15090 000

  • Novartis Investigative Site

    São Paulo, São Paulo, 01323 000

  • Novartis Investigative Site

    São Paulo, São Paulo, 04023-900

  • Novartis Investigative Site

    São Paulo, São Paulo, 05403-000

  • Novartis Investigative Site

    São Paulo, São Paulo, 05508-000

  • Novartis Investigative Site

    Tatuí, São Paulo, 18270-170

  • Novartis Investigative Site

    Uberlândia, Minas Gerais, 38405-320

  • Novartis Investigative Site

    Uberlândia, Minas Gerais, 38411 186

  • Novartis Investigative Site

    Votuporanga, São Paulo, 15500 003

Other trials in Brazil

China34 sites

  • Novartis Investigative Site

    Baotou, Inner Mongolia, 014040

  • Novartis Investigative Site

    Beijing, Beijing Municipality, 100730

  • Novartis Investigative Site

    Beijing, 100010

  • Novartis Investigative Site

    Beijing, 100028

  • Novartis Investigative Site

    Beijing, 100029

  • Novartis Investigative Site

    Beijing, 100034

  • Novartis Investigative Site

    Beijing, 100038

  • Novartis Investigative Site

    Beijing, 100176

  • Novartis Investigative Site

    Changchun, Jilin, 130033

  • Novartis Investigative Site

    Changsha, Hunan, 410003

  • Novartis Investigative Site

    Chongqing, Chongqing Municipality, 400010

  • Novartis Investigative Site

    Fuzhou, Fujian

  • Novartis Investigative Site

    Guangzhou, Guangdong, 510000

  • Novartis Investigative Site

    Guangzhou, Guangdong, 51000

  • Novartis Investigative Site

    Hangzhou, Zhejiang, 310013

  • Novartis Investigative Site

    Hangzhou, Zhejiang, 310016

  • Novartis Investigative Site

    Harbin, Heilongjiang, 150000

  • Novartis Investigative Site

    Nanjing, Jiangsu, 210009

  • Novartis Investigative Site

    Nanning, Guangxi, 530021

  • Novartis Investigative Site

    Shanghai, Shanghai Municipality, 200032

  • Novartis Investigative Site

    Shanghai, Shanghai Municipality, 200120

  • Novartis Investigative Site

    Shanghai, Shanghai Municipality

  • Novartis Investigative Site

    Shanghai, 200080

  • Novartis Investigative Site

    Shenyang, Liaoning, 110003

  • Novartis Investigative Site

    Shenyang, Liaoning, 110016

  • Novartis Investigative Site

    Shijiazhuang, Hebei, 050000

  • Novartis Investigative Site

    Suzhou, Jiangsu, 215006

  • Novartis Investigative Site

    Tianjin, Tianjin Municipality, 300121

  • Novartis Investigative Site

    Tianjin, 300142

  • Novartis Investigative Site

    Tianjin, 30045

  • Novartis Investigative Site

    Wuhan, Hubei, 430022

  • Novartis Investigative Site

    Wuhan, Hubei, 430060

  • Novartis Investigative Site

    Xian, Shanxi, 710004

  • Novartis Investigative Site

    Xian, Shanxi, 710061

Other trials in China

United Kingdom34 sites

  • Novartis Investigative Site

    Axbridge, Somerset, BS26 2BJ

  • Novartis Investigative Site

    Barnet, EN5 3DJ

  • Novartis Investigative Site

    Basingstoke, Hampshire, RG24 9NA

  • Novartis Investigative Site

    Berkshire, RG2 0TG

  • Novartis Investigative Site

    Birmingham, B15 2SQ

  • Novartis Investigative Site

    Birmingham, B15 2TH

  • Novartis Investigative Site

    Birmingham, B9 5SS

  • Novartis Investigative Site

    Cardiff, Wales, CF5 4AD

  • Novartis Investigative Site

    Cardiff, CF14 5GJ

  • Novartis Investigative Site

    Cheshire, CW11 1EQ

  • Novartis Investigative Site

    Chesterfield, S40 4AA

  • Novartis Investigative Site

    Chorley, PR7 7NA

  • Novartis Investigative Site

    Dundee, Perthshire, DD1 9SY

  • Novartis Investigative Site

    Exeter, EX2 5DW

  • Novartis Investigative Site

    Glasgow, G20 0SP

  • Novartis Investigative Site

    Glasgow, G20 0XA

  • Novartis Investigative Site

    Glasgow, G51 4TF

  • Novartis Investigative Site

    Irvine, KA12 0AY

  • Novartis Investigative Site

    Leicester, LE3 9QP

  • Novartis Investigative Site

    Liverpool, L22 0LG

  • Novartis Investigative Site

    London, EC14 7BE

  • Novartis Investigative Site

    Manchester, M15 6SX

  • Novartis Investigative Site

    Newcastle upon Tyne, NE7 7DN

  • Novartis Investigative Site

    Newport, Isle Of Wight, PO30 5TG

  • Novartis Investigative Site

    Newport, NP20 2UB

  • Novartis Investigative Site

    Norwich, NR4 7UY

  • Novartis Investigative Site

    Nottingham, NG5 1PB

  • Novartis Investigative Site

    Salford, Manchester, M6 8HD

  • Novartis Investigative Site

    Sheffield, S5 7AU

  • Novartis Investigative Site

    Taunton, Somerset, TA1 5DA

  • Novartis Investigative Site

    Whitby, North Yorkshire, Y021 1SD

  • Novartis Investigative Site

    Wiltshire, SN15 2SB

  • Novartis Investigative Site

    Worcester, WR5 1DD

  • Novartis Investigative Site

    York, YO31 8HE

Other trials in United Kingdom

Romania32 sites

  • Novartis Investigative Site

    Baia Mare, 430123

  • Novartis Investigative Site

    Brăila, ROM, 810249

  • Novartis Investigative Site

    Brasov, 500283

  • Novartis Investigative Site

    Bucharest, District 1, 010225

  • Novartis Investigative Site

    Bucharest, District 1

  • Novartis Investigative Site

    Bucharest, District 2

  • Novartis Investigative Site

    Bucharest, District 4, 4204179

  • Novartis Investigative Site

    Bucharest, 011728

  • Novartis Investigative Site

    Bucharest, 011774

  • Novartis Investigative Site

    Bucharest, 021659

  • Novartis Investigative Site

    Cluj-Napoca, Jud Cluj, 400015

  • Novartis Investigative Site

    Cluj-Napoca, 400006

  • Novartis Investigative Site

    Cluj-Napoca, 400347

  • Novartis Investigative Site

    Constanța, Jud. Constanta, 900591

  • Novartis Investigative Site

    Craiova, Jud. Dolj, 200497

  • Novartis Investigative Site

    Craiova, 200642

  • Novartis Investigative Site

    Iași, Jud Iasi, 700732

  • Novartis Investigative Site

    Iași, Jud. Iasi, 700111

  • Novartis Investigative Site

    Oradea, Jud Bihor, 410169

  • Novartis Investigative Site

    Oradea, 410169

  • Novartis Investigative Site

    Piteşti, Argeş, 110438

  • Novartis Investigative Site

    Piteşti, 110084

  • Novartis Investigative Site

    Sibiu, 550371

  • Novartis Investigative Site

    Târgu Mureş, Jud Mures, 540043

  • Novartis Investigative Site

    Târgu Mureş, Mureș County, 540124

  • Novartis Investigative Site

    Târgu Mureş, 540096

  • Novartis Investigative Site

    Târgu Mureş, 540136

  • Novartis Investigative Site

    Târgu Mureş, 540142

  • Novartis Investigative Site

    Tg Mures, Mureș County, 540136

  • Novartis Investigative Site

    Timișoara, Timiș County, 300362

  • Novartis Investigative Site

    Timișoara, 300310

  • Novartis Investigative Site

    Timișoara, 300736

Other trials in Romania

Czechia31 sites

  • Novartis Investigative Site

    Benešov, 25601

  • Novartis Investigative Site

    Brandýs nad Labem, Czech Republic, 250 01

  • Novartis Investigative Site

    Brno-Bohunice, 625 00

  • Novartis Investigative Site

    Broumov, 550 01

  • Novartis Investigative Site

    Jablonec nad Nisou, Czech Republic, 466 01

  • Novartis Investigative Site

    Kladno, Czech Republic, 272 80

  • Novartis Investigative Site

    Kolín, 280 20

  • Novartis Investigative Site

    Liberec, Czech Republic, 460 05

  • Novartis Investigative Site

    Louny, Czech Republic

  • Novartis Investigative Site

    Mariánské Lázně, 353 01

  • Novartis Investigative Site

    Most, CZE, 434 01

  • Novartis Investigative Site

    Ostrava, Czech Republic, 70200

  • Novartis Investigative Site

    Pardubice, 530 02

  • Novartis Investigative Site

    Pilsen, Czech Republic, 301 00

  • Novartis Investigative Site

    Prague, Czech Republic, 148 00

  • Novartis Investigative Site

    Prague, Czech Republic

  • Novartis Investigative Site

    Prague, CZE, 128 08

  • Novartis Investigative Site

    Prague, 12808

  • Novartis Investigative Site

    Prague 4 - Krc, 14059

  • Novartis Investigative Site

    Rožnov pod Radhoštěm, Czech Republic, 756 61

  • Novartis Investigative Site

    Semily, Czech Republic, 513 31

  • Novartis Investigative Site

    Slaný, 274 01

  • Novartis Investigative Site

    Svitavy, Czech Republic, 568 25

  • Novartis Investigative Site

    Teplice, 415 29

  • Novartis Investigative Site

    Třebíč, Czech Republic, 674 01

  • Novartis Investigative Site

    Trutnov, CZE, 46063

  • Novartis Investigative Site

    Uherské Hradiště, 68601

  • Novartis Investigative Site

    Ústí nad Labem, Czech Republic, 400 01

  • Novartis Investigative Site

    Ústí nad Orlicí, Czech Republic, 562 18

  • Novartis Investigative Site

    Vyškov, Czech Republic, 68001

  • Novartis Investigative Site

    Znojmo, Czech Republic, 66902

Other trials in Czechia

Slovakia31 sites

  • Novartis Investigative Site

    Banská Bystrica, 97401

  • Novartis Investigative Site

    Bardejov, 085 01

  • Novartis Investigative Site

    Bratislava, Slovak Republic, 826 06

  • Novartis Investigative Site

    Bratislava, 81369

  • Novartis Investigative Site

    Bratislava, 831 06

  • Novartis Investigative Site

    Bratislava, 841 07

  • Novartis Investigative Site

    Brezno, Slovak Republic, 977 42

  • Novartis Investigative Site

    Dubnica nad Váhom, 01841

  • Novartis Investigative Site

    Dunajská Streda, 929 01

  • Novartis Investigative Site

    Galanta, 92701

  • Novartis Investigative Site

    Komárno, Slovak Republic, 94575

  • Novartis Investigative Site

    Košice, Slovak Republic, 040 22

  • Novartis Investigative Site

    Košice, 040 01

  • Novartis Investigative Site

    Košice, 04001

  • Novartis Investigative Site

    Levice, 934 01

  • Novartis Investigative Site

    Lučenec, 984 01

  • Novartis Investigative Site

    Lučenec, 98403

  • Novartis Investigative Site

    Martin, 036 01

  • Novartis Investigative Site

    Nitra, 949 01

  • Novartis Investigative Site

    Nitra, 94901

  • Novartis Investigative Site

    Nové Zámky, 940 01

  • Novartis Investigative Site

    Nové Zámky, 94002

  • Novartis Investigative Site

    Považská Bystrica, Slovak Republic, 017 01

  • Novartis Investigative Site

    Prešov, Slovak Republic, 080 01

  • Novartis Investigative Site

    Prešov, Slovak Republic, 08001

  • Novartis Investigative Site

    Prešov, 081 01

  • Novartis Investigative Site

    Rimavská Sobota, Slovak Republic, 97901

  • Novartis Investigative Site

    Svidník, Slovak Republic, 08901

  • Novartis Investigative Site

    Trnava, 91702

  • Novartis Investigative Site

    Veľký Krtíš, Slovak Republic, 990 01

  • Novartis Investigative Site

    Žilina, 012 07

Other trials in Slovakia

Netherlands25 sites

  • Novartis Investigative Site

    Alkmaar, 1815 JD

  • Novartis Investigative Site

    Amersfoort, 3813 TZ

  • Novartis Investigative Site

    Amstelveen, 1186 AM

  • Novartis Investigative Site

    Amsterdam, 1090 HM

  • Novartis Investigative Site

    Amsterdam, 1105 AZ

  • Novartis Investigative Site

    Apeldoorn, DZ, 7334

  • Novartis Investigative Site

    Breda, 4811SW

  • Novartis Investigative Site

    Deventer, 7416 SE

  • Novartis Investigative Site

    Doetinchem, 7009 BL

  • Novartis Investigative Site

    Ede, 6716 RP

  • Novartis Investigative Site

    Gouda, 2803 HH

  • Novartis Investigative Site

    Groningen, NL-9711 SG

  • Novartis Investigative Site

    Haarlem, 2035 RC

  • Novartis Investigative Site

    Heerlen, 6419 PC

  • Novartis Investigative Site

    Hoorn, 1624 NP

  • Novartis Investigative Site

    Leeuwarden, 8934 AD

  • Novartis Investigative Site

    Maastricht, AZ, 5800

  • Novartis Investigative Site

    Meppel, 7943 KA

  • Novartis Investigative Site

    Nijmegen

  • Novartis Investigative Site

    Rotterdam, 3001 HG

  • Novartis Investigative Site

    Rotterdam, 3083 AN

  • Novartis Investigative Site

    Sneek, The Netherlands, 8601 ZR

  • Novartis Investigative Site

    Tiel, 4002 WP

  • Novartis Investigative Site

    Utrecht, 3584 CX

  • Novartis Investigative Site

    Venlo, 5912 BL

Other trials in Netherlands

Hungary20 sites

  • Novartis Investigative Site

    Budapest, 1042

  • Novartis Investigative Site

    Budapest, 1083

  • Novartis Investigative Site

    Budapest, 1122

  • Novartis Investigative Site

    Budapest, 1125

  • Novartis Investigative Site

    Budapest, 1134

  • Novartis Investigative Site

    Budapest, 1145

  • Novartis Investigative Site

    Budapest, H-1115

  • Novartis Investigative Site

    Csongrád, 6640

  • Novartis Investigative Site

    Debrecen, 4032

  • Novartis Investigative Site

    Gyula, 5700

  • Novartis Investigative Site

    Kistarcsa, 2143

  • Novartis Investigative Site

    Komárom, 2921

  • Novartis Investigative Site

    Miskolc, 3530

  • Novartis Investigative Site

    Mosonmagyaróvár, 9200

  • Novartis Investigative Site

    Nyiregyháza, 4400

  • Novartis Investigative Site

    Pécs, 7623

  • Novartis Investigative Site

    Szeged, H 6725

  • Novartis Investigative Site

    Székesfehérvár, H-8000

  • Novartis Investigative Site

    Szentes, 6600

  • Novartis Investigative Site

    Zalaegerszeg, Zala County, 8900

Other trials in Hungary

Sweden17 sites

  • Novartis Investigative Site

    Borås, 506 30

  • Novartis Investigative Site

    Gothenburg, Västra Götaland County, SE-413 45

  • Novartis Investigative Site

    Gothenburg, 416 85

  • Novartis Investigative Site

    Kristianstad, 291 85

  • Novartis Investigative Site

    Luleå, 972 33

  • Novartis Investigative Site

    Lund, 22142

  • Novartis Investigative Site

    Lund, 222 21

  • Novartis Investigative Site

    Malmö, 214 22

  • Novartis Investigative Site

    Mölndal, 431 80

  • Novartis Investigative Site

    Östersund, 831 83

  • Novartis Investigative Site

    Skanör, 239 33

  • Novartis Investigative Site

    Skellefteå, 931 86

  • Novartis Investigative Site

    Stockholm, 118 83

  • Novartis Investigative Site

    Stockholm, SE-111 35

  • Novartis Investigative Site

    Uddevalla, 451 50

  • Novartis Investigative Site

    Vällingby, 162 68

  • Novartis Investigative Site

    Västerås, 72189

Other trials in Sweden

Norway16 sites

  • Novartis Investigative Site

    Ålesund, NO-6026

  • Novartis Investigative Site

    Elverum, 2408

  • Novartis Investigative Site

    Hamar, 2317

  • Novartis Investigative Site

    Harstad, 9481

  • Novartis Investigative Site

    Hønefoss, 3501

  • Novartis Investigative Site

    Lillehammer, 2629

  • Novartis Investigative Site

    Moss, 1523

  • Novartis Investigative Site

    Nesttun, 5221

  • Novartis Investigative Site

    Oslo, 0303

  • Novartis Investigative Site

    Oslo, 0424

  • Novartis Investigative Site

    Sandefjord, 3211

  • Novartis Investigative Site

    Skedsmokorset, 2020

  • Novartis Investigative Site

    Stavanger, 4068

  • Novartis Investigative Site

    Tønsberg, 3116

  • Novartis Investigative Site

    Trondheim, 7011

  • Novartis Investigative Site

    Tynset, 2501

Other trials in Norway

Poland16 sites

  • Novartis Investigative Site

    Gdansk, 80-435

  • Novartis Investigative Site

    Gdynia, 81-157

  • Novartis Investigative Site

    Gdynia, 81-302

  • Novartis Investigative Site

    Gdynia, 81-423

  • Novartis Investigative Site

    Lublin, 20-538

  • Novartis Investigative Site

    Oława, 55-200

  • Novartis Investigative Site

    Ostrów Wielkopolski, 63-400

  • Novartis Investigative Site

    Poznan, 60-375

  • Novartis Investigative Site

    Poznan, 61-874

  • Novartis Investigative Site

    Puławy, 24100

  • Novartis Investigative Site

    Rumia, 84-230

  • Novartis Investigative Site

    Skierniewice, 96-100

  • Novartis Investigative Site

    Torun, 87-100

  • Novartis Investigative Site

    Warsaw, 04-073

  • Novartis Investigative Site

    Węgrów, 07-100

  • Novartis Investigative Site

    Włocławek, 87-800

Other trials in Poland

Colombia14 sites

  • Novartis Investigative Site

    Armenia

  • Novartis Investigative Site

    Baranquilla, Atlántico

  • Novartis Investigative Site

    Baranquilla

  • Novartis Investigative Site

    Barranquilla, Atlántico

  • Novartis Investigative Site

    Barranquilla, 080020

  • Novartis Investigative Site

    Barranquilla

  • Novartis Investigative Site

    Bogotá

  • Novartis Investigative Site

    Bucaramanga, Santander Department

  • Novartis Investigative Site

    Cali

  • Novartis Investigative Site

    Cartagena, Departamento de Bolívar

  • Novartis Investigative Site

    Cartegena, Colombia

  • Novartis Investigative Site

    Florida Blanca

  • Novartis Investigative Site

    Floridablanca, Santander Department, 57-7

  • Novartis Investigative Site

    Manizales, Caldas Department, 1700

Other trials in Colombia

Belgium13 sites

  • Novartis Investigative Site

    Aalst, 9300

  • Novartis Investigative Site

    Bonheiden, 2820

  • Novartis Investigative Site

    Brasschaat, 2930

  • Novartis Investigative Site

    Brussels, 1000

  • Novartis Investigative Site

    De Pinte, 9840

  • Novartis Investigative Site

    Genk, 3600

  • Novartis Investigative Site

    Ghent, 9000

  • Novartis Investigative Site

    Hasselt, 3500

  • Novartis Investigative Site

    Huy, 4500

  • Novartis Investigative Site

    Leuven, 3000

  • Novartis Investigative Site

    Mechelen, 2800

  • Novartis Investigative Site

    Ottignies, 1340

  • Novartis Investigative Site

    Tienen, 3300

Other trials in Belgium

South Korea13 sites

  • Novartis Investigative Site

    Busan, 49201

  • Novartis Investigative Site

    Busan, 602739

  • Novartis Investigative Site

    Busan, 612-896

  • Novartis Investigative Site

    Daegu, 705 718

  • Novartis Investigative Site

    Daegu, 705703

  • Novartis Investigative Site

    Daejeon, Korea, 35015

  • Novartis Investigative Site

    Gwangju, 61469

  • Novartis Investigative Site

    Seoul, Korea, 08308

  • Novartis Investigative Site

    Seoul, Seocho Gu, 06591

  • Novartis Investigative Site

    Seoul, 03722

  • Novartis Investigative Site

    Suwon, Gyeonggi-do, 443380

  • Novartis Investigative Site

    Uijeongbu-si, Gyeonggi-do, 480-717

  • Novartis Investigative Site

    Wŏnju, Gangwon-do, 26426

Other trials in South Korea

Taiwan13 sites

  • Novartis Investigative Site

    Changhua, 50006

  • Novartis Investigative Site

    Kaohsiung City, 80756

  • Novartis Investigative Site

    Kaohsiung City, 83301

  • Novartis Investigative Site

    Taichung, Taiwan ROC, 40201

  • Novartis Investigative Site

    Taichung, 40447

  • Novartis Investigative Site

    Tainan, 71004

  • Novartis Investigative Site

    Taipei, Taiwan, ROC, 11217

  • Novartis Investigative Site

    Taipei, 10002

  • Novartis Investigative Site

    Taipei, 10449

  • Novartis Investigative Site

    Taipei, 114

  • Novartis Investigative Site

    Taipei

  • Novartis Investigative Site

    Taoyuan, 33305

  • Novartis Investigative Site

    Yilan, 26058

Other trials in Taiwan

Australia12 sites

  • Novartis Investigative Site

    Bateman, Western Australia, 6150

  • Novartis Investigative Site

    Bundoora, Victoria, 3083

  • Novartis Investigative Site

    Garran, Australian Capital Territory, 2606

  • Novartis Investigative Site

    Geelong, Victoria, 3220

  • Novartis Investigative Site

    Gosford, New South Wales, 2250

  • Novartis Investigative Site

    Hobart, Tasmania, 7000

  • Novartis Investigative Site

    Joondalup, Western Australia, 6027

  • Novartis Investigative Site

    Kogarah, New South Wales, 2217

  • Novartis Investigative Site

    Liverpool, New South Wales, 2170

  • Novartis Investigative Site

    Milton, Queensland, 4064

  • Novartis Investigative Site

    Perth, Western Australia, 6000

  • Novartis Investigative Site

    Southport, Queensland, 4215

Other trials in Australia

Greece12 sites

  • Novartis Investigative Site

    Athens, GR, 14233

  • Novartis Investigative Site

    Athens, 106 76

  • Novartis Investigative Site

    Athens, 115 27

  • Novartis Investigative Site

    Athens, 12462

  • Novartis Investigative Site

    Chalcis, GR 341 00

  • Novartis Investigative Site

    Crete Heraklion, Greece, 714 09

  • Novartis Investigative Site

    Heraklion Crete, Greece, 711 10

  • Novartis Investigative Site

    Magoula, GR, 190 18

  • Novartis Investigative Site

    Pátrai, 265 00

  • Novartis Investigative Site

    Thessaloniki, GR, 564 03

  • Novartis Investigative Site

    Thessaloniki, GR, 570 10

  • Novartis Investigative Site

    Voula, GR, 166 73

Other trials in Greece

South Africa11 sites

  • Novartis Investigative Site

    Alberton, 1449

  • Novartis Investigative Site

    Bloemfontein, 9301

  • Novartis Investigative Site

    Cape Town, Western Cape, 7405

  • Novartis Investigative Site

    Cape Town, 7405

  • Novartis Investigative Site

    Cape Town, 7925

  • Novartis Investigative Site

    Centurion, 4001

  • Novartis Investigative Site

    Durban, KwaZulu-Natal, 4052

  • Novartis Investigative Site

    Johannesburg, 2193

  • Novartis Investigative Site

    Kempton Park, 1620

  • Novartis Investigative Site

    Pretoria, 0002

  • Novartis Investigative Site

    Western Cape, 7130

Other trials in South Africa

Bulgaria10 sites

  • Novartis Investigative Site

    Pazardzhik, 4400

  • Novartis Investigative Site

    Pleven, 5800

  • Novartis Investigative Site

    Plovdiv, 4000

  • Novartis Investigative Site

    Sofia, 1000

  • Novartis Investigative Site

    Sofia, 1202

  • Novartis Investigative Site

    Sofia, 1233

  • Novartis Investigative Site

    Sofia, 1309

  • Novartis Investigative Site

    Sofia, 1431

  • Novartis Investigative Site

    Sofia, 1527

  • Novartis Investigative Site

    Sofia, 1606

Other trials in Bulgaria

Lithuania10 sites

  • Novartis Investigative Site

    Alytus, LT-62386

  • Novartis Investigative Site

    Kaunas, LTU, LT 50161

  • Novartis Investigative Site

    Kaunas, LT-44320

  • Novartis Investigative Site

    Kaunas, LT-49387

  • Novartis Investigative Site

    Kaunas, LT-49449

  • Novartis Investigative Site

    Kėdainiai, LT-57164

  • Novartis Investigative Site

    Klaipėda, LTU, LT-92288

  • Novartis Investigative Site

    Panevezys, LT-37460

  • Novartis Investigative Site

    Šiauliai, LT-76231

  • Novartis Investigative Site

    Vilnius, LT-08661

Other trials in Lithuania

Croatia9 sites

  • Novartis Investigative Site

    Čakovec, 40000

  • Novartis Investigative Site

    Koprivnica, 48000

  • Novartis Investigative Site

    Krapinske Toplice, 49 217

  • Novartis Investigative Site

    Krapinske Toplice, 49217

  • Novartis Investigative Site

    Opatija, 51410

  • Novartis Investigative Site

    Rijeka, 51000

  • Novartis Investigative Site

    Varaždin, HRV, 42000

  • Novartis Investigative Site

    Virovitica, 33000

  • Novartis Investigative Site

    Zagreb, 10000

Other trials in Croatia

Estonia9 sites

  • Novartis Investigative Site

    Pärnu, 80010

  • Novartis Investigative Site

    Saku, 75501

  • Novartis Investigative Site

    Tallinn, 10138

  • Novartis Investigative Site

    Tallinn, 10611

  • Novartis Investigative Site

    Tallinn, 13419

  • Novartis Investigative Site

    Tallinn, 13619

  • Novartis Investigative Site

    Tartu, 50410

  • Novartis Investigative Site

    Viljandi County, 71024

  • Novartis Investigative Site

    Võru, 65608

Other trials in Estonia

Turkey (Türkiye)8 sites

  • Novartis Investigative Site

    Aydin, 09100

  • Novartis Investigative Site

    Eskişehir, Meselik, 26480

  • Novartis Investigative Site

    Istanbul, 34304

  • Novartis Investigative Site

    Izmir, 35040

  • Novartis Investigative Site

    Izmir, 35340

  • Novartis Investigative Site

    Kocaeli, 41380

  • Novartis Investigative Site

    Mersin, 33079

  • Novartis Investigative Site

    Sivas, 58140

Other trials in Turkey (Türkiye)

Austria7 sites

  • Novartis Investigative Site

    Graz, A-8036

  • Novartis Investigative Site

    Linz, 4010

  • Novartis Investigative Site

    Linz, A-4010

  • Novartis Investigative Site

    Saint Stefan, Austria, 8511

  • Novartis Investigative Site

    Salzburg, A-5020

  • Novartis Investigative Site

    Vienna, 1030

  • Novartis Investigative Site

    Vienna, A 1090

Other trials in Austria

Mexico7 sites

  • Novartis Investigative Site

    Aguascalientes, 20230

  • Novartis Investigative Site

    Culiacán, Sinaloa, 80230

  • Novartis Investigative Site

    Guadalajara, Jalisco, 44210

  • Novartis Investigative Site

    Guadalajara, Jalisco, 44280

  • Novartis Investigative Site

    Querétaro, 76000

  • Novartis Investigative Site

    San Luis Potosí City, San Luis Potosí, 78240

  • Novartis Investigative Site

    San Luis Potosí City, 78200

Other trials in Mexico

Puerto Rico7 sites

  • Novartis Investigative Site

    Manati, 00674

  • Novartis Investigative Site

    Mayagüez, 00680

  • Novartis Investigative Site

    Ponce, 00716

  • Novartis Investigative Site

    Ponce, 00717

  • Novartis Investigative Site

    San Juan, 00909

  • Novartis Investigative Site

    San Juan, 00926

  • Novartis Investigative Site

    San Juan, 00936-6528

Other trials in Puerto Rico

Latvia6 sites

  • Novartis Investigative Site

    Daugavpils, LV-5417

  • Novartis Investigative Site

    Liepāja, LV, LV-3414

  • Novartis Investigative Site

    Riga, LV, LV-1005

  • Novartis Investigative Site

    Riga, 1012

  • Novartis Investigative Site

    Valmiera, 4201

  • Novartis Investigative Site

    Ventspils, LV, LV-3601

Other trials in Latvia

Guatemala4 sites

  • Novartis Investigative Site

    Guatemala City, 01001

  • Novartis Investigative Site

    Guatemala City, 01010

  • Novartis Investigative Site

    Guatemala City, 01011

  • Novartis Investigative Site

    Guatemala City, 01015

Other trials in Guatemala

Peru4 sites

  • Novartis Investigative Site

    Bellavista, Lima region, CALLAO 02

  • Novartis Investigative Site

    Lima, LIMA 39

  • Novartis Investigative Site

    San Isidro, Lima region, 27

  • Novartis Investigative Site

    San Martín de Porres, Lima region, 31

Other trials in Peru

Serbia4 sites

  • Novartis Investigative Site

    Belgrade, 11040

  • Novartis Investigative Site

    Kamenitz, 21204

  • Novartis Investigative Site

    Niš, 18000

  • Novartis Investigative Site

    Niška Banja, 18205

Other trials in Serbia

Iceland3 sites

  • Novartis Investigative Site

    Kopavogur, 201

  • Novartis Investigative Site

    Reykjavik, IS-101

  • Novartis Investigative Site

    Reykjavik, IS-109

Other trials in Iceland

Slovenia3 sites

  • Novartis Investigative Site

    Celje, 3000

  • Novartis Investigative Site

    Golnik, 4204

  • Novartis Investigative Site

    Ljubljana, 1000

Other trials in Slovenia

About this study

Official title: A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP

Main Study (CACZ885M2301): The purpose of the pivotal phase of this trial was to test the hypothesis that canakinumab treatment of patients with myocardial infarction (MI) at least one month prior to study entry and elevated hsCRP could prevent recurrent cardiovascular events.

The purpose of the extension phase of the main study is to collect additional long-term safety data on continued exposure to canakinumab in patients who participated in the pivotal phase.

Read more

Sub-study 1 (CACZ885M2301S1): The purpose of this sub-study was to evaluate the effect of quarterly subcutaneous canakinumab treatment for 24 months comparted with placebo on the carotid plaque burden measured by integrated vascular MRI in patients enrolled in the CACZ885M2301 study (CANTOS).

Sub-study 2 (CACZ885M2301S2): The purpose of this CANTOS sub-study was to determine whether, in patients with type 2 diabetes participating in the CANTOS main study, canakinumab compared to placebo, on top of standard of care could increase insulin secretion and insulin sensitivity.

Read the detailed description

Sub-study 1 and 2 were terminated prior to data collection from subjects. However, there is an ongoing extension trial where patients are receiving open-drug label.

Conditions
Atherosclerosis
Being tested
Canakinumab, Placebo, Standard of care
Keywords
Cardiovascular Death, Myocardial Infarction, Stroke, Canakinumab, IL-1B, hsCRP
Medical subject headings
Atherosclerosis, Myocardial Infarction, Stroke

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CanakinumabDrug

    Also called ACZ885

  • PlaceboDrug

  • Standard of careDrug

    Standard of care post-MI background therapy includes, but is not limited to, lipid lowering, anti-hypertensive, beta blockers, and anti-platelet therapy as appropriate

Study groups in NCT01327846
Study groupRoleWhat they receive
Canakinumab Dose 50 mgExperimentalPivotal Phase: Blinded Canakinumab 50 mg quarterly subcutaneous + standard of care therapy. Extension Phase: Switched to open-label Canakinumab 150 mg quarterly subcutaneous + standard of care therapy
Receives: Drug: Canakinumab; Drug: Standard of care
Canakinumab Dose 150 mgExperimentalPivotal Phase: Switched to open-label Canakinumab 150 mg quarterly subcutaneous + standard of care therapy
Receives: Drug: Canakinumab; Drug: Standard of care
Canakinumab Dose 300 mgExperimentalPivotal Phase: Blinded Canakinumab 300 mg quarterly subcutaneous (with one additional dose at week 2) + standard of care therapy. Extension phase: Switched to open-label Canakinumab 150 mg quarterly subcutaneous + standard of care therapy
Receives: Drug: Canakinumab; Drug: Standard of care
PlaceboPlacebo comparatorPivotal Phase: Blinded matching placebo quarterly subcutaneous + standard of care therapy. Extension Phase: Switched to open-label Canakinumab 150 mg quarterly subcutaneous + standard of care therapy
Receives: Drug: Placebo; Drug: Standard of care

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Analysis of Core Phase First CEC Confirmed Major Adverse Cardiovascular Events (MACE) and Its Components

    Time to occurrence of CEC (Cardiovascular clinical events adjudication committee) confirmed MACE, which was a composite endpoint consisting of CEC confirmed CV death, CEC confirmed non-fatal MI,or CEC confirmed non-fatal stroke. Patients with the CEC adjudicated reason for death of "Unknown" were counted as CV (cardiovascular) death.

    Measured: From randomization, to end of treatment plus 30 days, up to approximately 6 years

  2. Substudy 1 (Core Phase): Change From Baseline in Carotid Plaque Burden in the Bifurcation Region of the Index Carotid Artery

    Measured: 24 months

  3. Substudy 2 (Core Phase): Change From Baseline of the Insulin Secretion Rate (ISR) Relative to Glucose 0-30 Min Defined as Φ30 = AUCISR 0-30 / AUCGluc 0-30 Averaged Across the Year 3, 4, 5 Visits

    Measured: From randomization up to approximately 6 years

Secondary outcomes (14)

  1. Patients With Core Phase CEC Confirmed CV Death, Non-fatal MI, Non-fatal Stroke, or Hospitalization for Unstable Angina Requiring Unplanned Revascularization

    Occurrence of the composite cardiovascular endpoint consisting of cardiovascular death, non-fatal MI, non-fatal stroke or hospitalization for unstable angina requiring unplanned revascularization.

    MACE includes CV death, non-fatal MI and non-fatal stroke. CEC = Clinical Endpoints Committee

    Measured: From randomization, to end of treatment pus 30 days, up to approximately 6 years

  2. Patients With Core Phase New Onset Type 2 Diabetes Among Patients With Pre-diabetes at Randomization

    Time to CEC confirmed new onset of type 2 diabetes among those with pre-diabetes at randomization (i.e. excluding those that are normoglycemic at baseline)

    Measured: From randomization up to approximately 6 years

  3. Core Phase All-cause Mortality, Non-fatal MI, or Non-fatal Stroke

    Occurrence of the composite endpoint consisting of all-cause mortality, non-fatal IM, or non-fatal stroke

    Measured: From randomization, to end of treatment plus 30 days, up to approximately 6 years

  4. Core Phase All-cause Mortality

    Number of participant deaths

    Measured: From randomization, to end of treatment plus 30 days, up to approximately 6 years

  5. Summary of Adverse Events (Core Phase)

    Summary of Adverse Events (AEs) and Serious Adverse Events (SAEs) occurring during the double-blind Core phase of the study. AEs/SAEs are any signs or symptoms that occur during the study treatment.

    Measured: From randomization, to end of treatment plus 30 days, up to approximately 6 years

  6. Summary of Adverse Events (Extension Phase)

    Summary of Adverse Events (AEs) and Serious Adverse Events (SAEs) occurring during the Extension phase of the study. AEs/SAEs are any signs or symptoms that occur during the study treatment.

    Measured: From start of Extension phase, to end of treatment plus 30 days, up to approximately 2 years

  7. Substudy 1 (Core Phase): Change From Baseline of the Total Vessel Wall Area at Month 3 in the Bifurcation Region of the Index Carotid Artery

    Measured: 3 months

  8. Substudy 1 (Core Phase): Mean Total Vessel Wall Area Across the Left and Right Carotid Artery at Month 3 and Month 24

    Measured: 24 months

  9. Substudy 1 (Core Phase): Change From Baseline in Corresponding Total Vessel Wall Area in the Left and Right Carotid Arteries

    Measured: 24 months

  10. Substudy 1 (Core Phase): The Existence of a Baseline Total Vessel Wall Area by Treatment Interaction as Well as the Consistency of the Treatment Effect Across Subgroups

    Measured: 24 months

  11. Substudy 2 (Core Phase): Change From Baseline in Insulin Sensitivity Index

    Measured: From randomization up to approximately 6 years

  12. Substudy 2 (Core Phase): Change From Baseline in OGTT Stimulated Area Under Curve (AUC) 0-120 Min of Glucose Concentration, Insulin Concentration, Pro-insulin Concentration, and Insulin Concentration/Glucose Concentration Ratio

    Measured: From randomization up to approximately 6 years

  13. Substudy 2 (Core Phase): Change From Baseline in Fasting Pro-Insulin Concentration/Insulin Concentration Ratio

    Measured: From randomization up to approximately 6 years

  14. Substudy 2 (Core Phase): Change From Baseline in OGTT Stimulated Area Under the Curve (AUC) 0-120 Min of C-peptide Concentration

    Measured: From randomization up to approximately 6 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Apr 2011 (estimated)
  2. Study start11 Apr 2011
  3. Primary completion28 Mar 2017
  4. Study completion14 Apr 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
10,066 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01327846
Sponsor's protocol ID
CACZ885M2301
Other IDs
2010-022970-14
Acronym
CANTOS
Status last verified
Jan 2020
First submitted
29 Mar 2011
Last updated
22 Jan 2020
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Publications

  • Scheidegger C, Wandel S, Mutze T. Covariate Adjustment for the Win Odds: Application to Cardiovascular Outcomes Trials. Stat Med. 2026 May;45(10-12):e70602. doi: 10.1002/sim.70602.

    PubMed 42141513

  • Woo J, Zhai T, Yang F, Xu H, Healey ML, Yates DP, Beste MT, Steensma DP. Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial. Cancer Prev Res (Phila). 2024 Sep 4;17(9):429-436. doi: 10.1158/1940-6207.CAPR-23-0342.

    PubMed 38701435

  • Woo J, Lu D, Lewandowski A, Xu H, Serrano P, Healey M, Yates DP, Beste MT, Libby P, Ridker PM, Steensma DP. Effects of IL-1beta inhibition on anemia and clonal hematopoiesis in the randomized CANTOS trial. Blood Adv. 2023 Dec 26;7(24):7471-7484. doi: 10.1182/bloodadvances.2023011578.

    PubMed 37934948

  • Ridker PM, Tuttle KR, Perkovic V, Libby P, MacFadyen JG. Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy. Eur Heart J. 2022 Dec 7;43(46):4832-4844. doi: 10.1093/eurheartj/ehac444.

    PubMed 35943897

  • Svensson EC, Madar A, Campbell CD, He Y, Sultan M, Healey ML, Xu H, D'Aco K, Fernandez A, Wache-Mainier C, Libby P, Ridker PM, Beste MT, Basson CT. TET2-Driven Clonal Hematopoiesis and Response to Canakinumab: An Exploratory Analysis of the CANTOS Randomized Clinical Trial. JAMA Cardiol. 2022 May 1;7(5):521-528. doi: 10.1001/jamacardio.2022.0386.

    PubMed 35385050

  • Everett BM, MacFadyen JG, Thuren T, Libby P, Glynn RJ, Ridker PM. Inhibition of Interleukin-1beta and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial. J Am Coll Cardiol. 2020 Oct 6;76(14):1660-1670. doi: 10.1016/j.jacc.2020.08.011.

    PubMed 33004131

  • Schieker M, Conaghan PG, Mindeholm L, Praestgaard J, Solomon DH, Scotti C, Gram H, Thuren T, Roubenoff R, Ridker PM. Effects of Interleukin-1beta Inhibition on Incident Hip and Knee Replacement : Exploratory Analyses From a Randomized, Double-Blind, Placebo-Controlled Trial. Ann Intern Med. 2020 Oct 6;173(7):509-515. doi: 10.7326/M20-0527. Epub 2020 Aug 4.

    PubMed 32744862

  • Vallurupalli M, MacFadyen JG, Glynn RJ, Thuren T, Libby P, Berliner N, Ridker PM. Effects of Interleukin-1beta Inhibition on Incident Anemia: Exploratory Analyses From a Randomized Trial. Ann Intern Med. 2020 Apr 21;172(8):523-532. doi: 10.7326/M19-2945. Epub 2020 Mar 24.

    PubMed 32203978

  • Rothman AM, MacFadyen J, Thuren T, Webb A, Harrison DG, Guzik TJ, Libby P, Glynn RJ, Ridker PM. Effects of Interleukin-1beta Inhibition on Blood Pressure, Incident Hypertension, and Residual Inflammatory Risk: A Secondary Analysis of CANTOS. Hypertension. 2020 Feb;75(2):477-482. doi: 10.1161/HYPERTENSIONAHA.119.13642. Epub 2019 Dec 30.

    PubMed 31884854

  • Ridker PM, MacFadyen JG, Thuren T, Libby P. Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1beta inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis. Eur Heart J. 2020 Jun 14;41(23):2153-2163. doi: 10.1093/eurheartj/ehz542.

    PubMed 31504417

  • Everett BM, Cornel JH, Lainscak M, Anker SD, Abbate A, Thuren T, Libby P, Glynn RJ, Ridker PM. Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure. Circulation. 2019 Mar 5;139(10):1289-1299. doi: 10.1161/CIRCULATIONAHA.118.038010.

    PubMed 30586730

  • Solomon DH, Glynn RJ, MacFadyen JG, Libby P, Thuren T, Everett BM, Ridker PM. Relationship of Interleukin-1beta Blockade With Incident Gout and Serum Uric Acid Levels: Exploratory Analysis of a Randomized Controlled Trial. Ann Intern Med. 2018 Oct 16;169(8):535-542. doi: 10.7326/M18-1167. Epub 2018 Sep 18.

    PubMed 30242335

  • Ridker PM, Libby P, MacFadyen JG, Thuren T, Ballantyne C, Fonseca F, Koenig W, Shimokawa H, Everett BM, Glynn RJ. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Eur Heart J. 2018 Oct 7;39(38):3499-3507. doi: 10.1093/eurheartj/ehy310.

    PubMed 30165610

  • Ridker PM, MacFadyen JG, Glynn RJ, Koenig W, Libby P, Everett BM, Lefkowitz M, Thuren T, Cornel JH. Inhibition of Interleukin-1beta by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease. J Am Coll Cardiol. 2018 May 29;71(21):2405-2414. doi: 10.1016/j.jacc.2018.03.490.

    PubMed 29793629

  • Everett BM, Donath MY, Pradhan AD, Thuren T, Pais P, Nicolau JC, Glynn RJ, Libby P, Ridker PM. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. J Am Coll Cardiol. 2018 May 29;71(21):2392-2401. doi: 10.1016/j.jacc.2018.03.002. Epub 2018 Mar 12.

    PubMed 29544870

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Canakinumab in people with Atherosclerosis, run by Novartis Pharmaceuticals at 1,131 sites in 40 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 22 Jan 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1,131 sites in United States, Germany, Argentina, Russia, India and 35 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 22 Jan 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Analysis of Core Phase First CEC Confirmed Major Adverse Cardiovascular Events (MACE) and Its Components (time frame: From randomization, to end of treatment plus 30 days, up to approximately 6 years). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01327846, which also lists 20 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jan 2020.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in